Testing effectiveness (Phase 2)Looking for participantsNCT07239011What this trial is testingDapagliflozin in DepressionWho this might be right forDepression Tanta University 60
Not applicableEnrolling By InvitationNCT05029115What this trial is testingThe Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes MellitusWho this might be right forSGLT-2 InhibitorAtrial FibrillationDiabetes Mellitus, Type 2 Ewha Womans University Mokdong Hospital 716
Large-scale testing (Phase 3)Active Not RecruitingNCT07214818What this trial is testingSGLT2 Inhibitors in Adult Primary Nephrotic SyndromeWho this might be right forNephrotic Syndrome Mansoura University 75
Testing effectiveness (Phase 2)Study completedNCT04911660What this trial is testingImpact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone FormersWho this might be right forKidney Stone Insel Gruppe AG, University Hospital Bern 50
Not applicableStudy completedNCT02297620What this trial is testingThe Survey of Ipragliflozin Treatment in Elderly type2 Diabetes PatientsWho this might be right forType 2 Diabetes Astellas Pharma Inc 8,687
Testing effectiveness (Phase 2)UnknownNCT04304560What this trial is testingValue of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical TrialWho this might be right forHeart Failure With Reduced Ejection Fraction (HFrEF)Diabete Type 2Cardiomyopathies Damanhour University 60
Early research (Phase 1)Looking for participantsNCT05521984What this trial is testingTargeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)Who this might be right forPediatric Brain TumorPediatric Solid Tumor Washington University School of Medicine 20
Post-approval studies (Phase 4)Study completedNCT06026787What this trial is testingClinical Value of Adding Dapagliflozin in Patients With Nephrotic SyndromeWho this might be right forNephrotic SyndromeSodium-Glucose Transporter 2 Inhibitors Ain Shams University 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06149793What this trial is testingSGLT2 Inhibitor Therapy in Cystic Fibrosis-related DiabetesWho this might be right forCystic Fibrosis-related DiabetesCystic Fibrosis University of Minnesota 8
Not applicableStudy completedNCT07338331What this trial is testingComparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver DiseaseWho this might be right forDiabete Type 2Non Alcoholic Fatty Liver Galala University 80
Post-approval studies (Phase 4)UnknownNCT02719756What this trial is testingEffect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2Who this might be right forDiabetes MellitusHypoglycemic Episodes Research Clinical Centre of the Russian Railways, JSC 100
Not applicableActive Not RecruitingNCT05890131What this trial is testingImplementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital StrategyWho this might be right forHeart Failure Morten Schou 5,996
Not applicableUnknownNCT04961931What this trial is testingEffect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney DiseaseWho this might be right forChronic Kidney Disease stage3 Medical University of Lodz 45
Early research (Phase 1)Looking for participantsNCT05960656What this trial is testingSGLTi, Hepatic Glucose Production and KetogenesisWho this might be right forType 2 Diabetes The University of Texas Health Science Center at San Antonio 30
Post-approval studies (Phase 4)UnknownNCT04796428What this trial is testingGliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialWho this might be right forDiabetes Mellitus, Type 2 Center for Outcomes Research and Clinical Epidemiology, Italy 1,167
Post-approval studies (Phase 4)Study completedNCT03267576What this trial is testingAn Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminWho this might be right forDiabetes Mellitus, Type 2 Janssen Research & Development, LLC 64
Large-scale testing (Phase 3)Study completedNCT06109311What this trial is testingOrforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorWho this might be right forType 2 Diabetes Eli Lilly and Company 546
Post-approval studies (Phase 4)Study completedNCT03646292What this trial is testingAntidiabetic Drugs for Steatotic Liver DiseaseWho this might be right forMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesDigestive System Disease+11 more Yonsei University 51
Not applicableStudy completedNCT05344963What this trial is testingDeformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 InhibitorsWho this might be right forSodium-GLucose coTransporter-2 InhibitorsHeart Failure With Reduced Ejection Fraction Matteo Cameli 503
Post-approval studies (Phase 4)Study completedNCT03226457What this trial is testingSGLT2 Inhibition in Combination With Diuretics in Heart FailureWho this might be right forHeart FailureType 2 Diabetes Mellitus University of Dundee 23